Related Experiment Video
Updated: May 4, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
Published on: July 14, 2023
Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a
Romina di Giuseppe1, Brian Buijsse, Frank Hirche
1Department of Epidemiology (R.d.G., B.B., J.W., M.A., H.B., C.W.), German Institute of Human Nutrition Potsdam-Rehbrücke, D-14558 Nuthetal, Germany; Institute of Agricultural and Nutritional Sciences (F.H., G.I.S.), Human Nutrition Group, Martin-Luther-University Halle-Wittenberg, D-06108 Halle, Germany; Department for Clinical Chemistry and Pathobiochemistry (S.W., B.I.), Otto-von-Guericke-University Magdeburg, 39106 Magdeburg, Germany; Institute of Epidemiology and Social Medicine (H.W.H.), Clinical Epidemiology Unit, University of Münster, D-48129 Münster, Germany; Department of Clinical Medicine (J.D.), University of Bergen, N-5020 Bergen Norway; and Institute for Social Medicine, Epidemiology, and Health Economics (C.W.), Charité University Medical Center, 10117 Berlin, Germany.
Insights
Higher levels of fibroblast growth factor 23 (FGF23) are linked to an increased risk of heart failure (HF). The study found no clear association for parathyroid hormone (PTH) or 25-hydroxyvitamin D3 [25(OH)D3] with HF risk.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Research
Background:
- Bone mineral metabolism is increasingly recognized for its potential role in the pathogenesis of heart failure (HF).
- Specific biomarkers such as fibroblast growth factor 23 (FGF23), parathyroid hormone (PTH), and 25-hydroxyvitamin D3 [25(OH)D3] are implicated in mineral metabolism and may influence cardiovascular health.
Purpose of the Study:
- To investigate the association between plasma levels of FGF23, PTH, and 25(OH)D3 and the incidence of congestive heart failure (HF).
- To examine these relationships in a population-based cohort of middle-aged men and women.
Main Methods:
- A prospective case-cohort study was conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort.
- The study included 221 incident congestive HF cases and 1228 individuals without HF, with a mean follow-up of 8.2 years.
Main Results:
- Each doubling of FGF23 was associated with a 29% increased risk of HF (HR, 1.29; 95% CI, 1.07-1.56) after multivariable adjustment.
- PTH was not significantly related to HF risk (HR per doubling, 1.21; 95% CI, 0.99-1.48), although an interaction with obesity suggested a potential link.
- No significant association was found between 25(OH)D3 and HF risk (HR per doubling, 1.02; 95% CI, 0.73-1.41).
Conclusions:
- Epidemiological evidence supports a positive relationship between elevated FGF23 levels and an increased risk of developing heart failure.
- The role of PTH in HF development requires further investigation, particularly in obese populations.
- Plasma 25(OH)D3 levels do not appear to be associated with incident HF in this cohort.
Context:
Bone mineral metabolism may play a role in the development of heart failure (HF).
Objective:
The aim of the study was to investigate the relationships of plasma fibroblast growth factor (FGF) 23, PTH, and 25-hydroxyvitamin D3 [25(OH)D3] with incident congestive HF in a population-based cohort of men and women aged 40-65 and 35-65 years, respectively, at baseline.
Design:
We conducted a prospective case-cohort study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort, including a randomly drawn sample of the total cohort free of HF and all incident HF cases that occurred during a mean follow-up of 8.2 ± 1.6 years.
Participants And Setting:
A total of 221 incident congestive HF cases and 1228 individuals free of HF were included in the study.
Main Outcome Measures:
Incident congestive HF was measured.
Results:
In a multivariable model, each doubling of FGF23 [ie, per log (base 2) unit higher FGF23] was associated with a 29% higher HF risk (hazard ratio, 1.29 [95% confidence interval (CI), 1.07-1.56]). After multivariable adjustment, including estimated glomerular filtration rate, PTH was not related to HF risk (hazard ratio per doubling of PTH, 1.21 [95% CI, 0.99-1.48]). However, an interaction was observed between PTH and obesity, suggesting a relationship with HF risk in obese, but not in nonobese individuals. The hazard ratio for HF per doubling of 25(OH)D3 was 1.02 (95% CI, 0.73-1.41).
Conclusions:
Our findings provide epidemiological evidence for a positive relationship between FGF23 and risk of HF. The role of PTH in the development of HF remains unclear, in particular in obese individuals, until further confirmation in other studies. 25(OH)D3 was not related to HF.
More Related Videos
06:47Isolation of Mesenchymal Stem Cells from Human Alveolar Periosteum and Effects of Vitamin D on Osteogenic Activity of Periosteum-derived Cells
Published on: May 4, 2018
11:30A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Related Concept Videos
Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily...
Skeleton and Calcium Homeostasis
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
The Parathyroid Glands
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...